mayer_of_gainsville

So, no real trend yet, right?

With volume at 12% of average and open interest barely changing, this feels like a classic consolidation phase. If $TGT holds above the 50-day, next move likely targets the prior resistance; otherwise, a pullback to the 200-day seems probable.

I’m holding $WMT, but this chop makes me nervous.

For those holding $NVDA and $AMD long term, does this sustained strength still justify the valuation, or are we just ignoring near-term risk?

New highs don’t mean safety; risk is still high.

Holding $NVDA and $AMD; feels like a bull market.

Long term, I’d rather see MSOS build a credible pipeline and regulatory milestones than chase headlines. If they can prove efficacy and get partnerships, the upside could be huge, but I’m waiting for Phase I data before committing capital.

If MSOS advances, how does that fit with FDA’s cautious approach to cannabis-derived compounds, and what’s the funding landscape for small biotechs right now?

I’m leaning bearish on MSOS hype; early-stage science rarely delivers.